Publications

Found 106 results
[ Type(Desc)] Year
Conference Paper
J Black, A Adler, H Hutchinson, H Wang, G Pitt, K Leong, and C Gersbach. "59. Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
KA Glass, AK Ross, SA Compton, CA Gersbach, FT Moutos, BT Estes, and F Guilak. "Anatomically-Shaped Tissue-Engineered Cartilage with Tunable and Inducible Anti-Inflammatory Capabilities." In Tissue Engineering, Part A, S330. Vol. 21. 2015.
N Farhang, JM Brunger, JD Stover, PI Thakore, BD Lawrence, F Guilak, CA Gersbach, LA Setton, and RD Bowles. "CRISPRi Immunomodulation for Tissue Engineering/Stem Cell Therapies Targeting Intervertebral Disc Degeneration." In Tissue Engineering, Part A, S170. Vol. 21. 2015.
J Black, A Adler, H Hutchinson, H Wang, G Pitt, K Leong, and C Gersbach. "Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
E Schulz, T Bergmann, M Gebbing, V Schildgen, O Schildgen, C Gersbach, and A Ehrhardt. "Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods." In Molecular Therapy, S126-S127. Vol. 22. 2014.
P Perez-Pinera, DG Ousterout, JM Brunger, AM Farin, KA Glass, F Guilak, GE Crawford, AJ Hartemink, and CA Gersbach. "Synergistic and Tunable Gene Activation by Combinations of Synthetic Transcription Factors." In Molecular Therapy, S93. Vol. 21. 2013.
KA Glass, JM Brunger, CA Gersbach, and F Guilak. "TUNABLE EXPRESSION OF IL-1RA IN GENETICALLY MODIFIED MESENCHYMAL STEM CELLS FOR CARTILAGE TISSUE ENGINEERING." In Osteoarthritis and Cartilage, S282-S283. Vol. 21. 2013.
Journal Article
CA Gersbach, and P Perez-Pinera. "Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine." Expert Opinion on Therapeutic Targets 18, no. 8 (2014): 835-839.
AJ García, RE Guldberg, BA Byers, CA Gersbach, and JE Phillips. "Addressing cell-sourcing limitations with gene therapy." IEEE Engineering in Medicine and Biology Magazine 22, no. 5 (2003): 65-70.
P Perez-Pinera, DG Ousterout, and CA Gersbach. "Advances in targeted genome editing." Current Opinion in Chemical Biology 16, no. 3-4 (2012): 268-277.
FT Moutos, KA Glass, SA Compton, AK Ross, CA Gersbach, F Guilak, and BT Estes. "Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing." Proceedings of the National Academy of Sciences of USA 113, no. 31 (2016): E4513-E4522.
GP Pathak, JI Spiltoir, C Höglund, LR Polstein, S Heine-Koskinen, CA Gersbach, J Rossi, and CL Tucker. "Bidirectional approaches for optogenetic regulation of gene expression in mammalian cells using Arabidopsis cryptochrome 2." Nucleic Acids Research 45, no. 20 (2017).
CA Gersbach,, JM Le Doux, and AJ García. "Biomaterial-mediated retroviral gene transfer using self-assembled monolayers." Biomaterials 28, no. 34 (2007): 5121-5127.
M Gemberling, and CA Gersbach. "Boosting, Not Breaking: CRISPR Activators Treat Disease Models." Molecular Therapy 26, no. 2 (2018): 334-336.
CE Nelson, and CA Gersbach. "Cas9 loosens its grip on off-target sites." Nature Biotechnology 34, no. 3 (2016): 298-299.
CA Gersbach, T Gaj, and CF Barbas. "Comparing Genome Editing Technologies." Genetic Engineering and Biotechnology News 34, no. 5 (2014): 1, 32-34.
DG Ousterout, AM Kabadi, PI Thakore, P Perez-Pinera, MT Brown, WH Majoros, TE Reddy, and CA Gersbach. "Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy 23, no. 3 (2015): 523-532.
DG Ousterout, AM Kabadi, PI Thakore, P Perez-Pinera, MT Brown, WH Majoros, TE Reddy, and CA Gersbach. "Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy 23, no. 3 (2015): 523-532.
K High, PD Gregory, and C Gersbach. "CRISPR technology for gene therapy." Nature Medicine 20, no. 5 (2014): 476-477.
N Farhang, JM Brunger, JD Stover, PI Thakore, B Lawrence, F Guilak, CA Gersbach, LA Setton, and RD Bowles. "CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments." Tissue Engineering, Part A 23, no. 15-16 (2017): 738-749.
TS Klann, JB Black, and CA Gersbach. "CRISPR-based methods for high-throughput annotation of regulatory DNA." Current Opinion in Biotechnology 52 (2018): 32-41.
JM Brunger, A Zutshi, VP Willard, CA Gersbach, and F Guilak. "CRISPR/Cas9 editing of induced pluripotent stem cells for engineering inflammation-resistant tissues." Arthritis and Rheumatology 69, no. 5 (2016): 1111-1121.
TS Klann, JB Black, M Chellappan, A Safi, L Song, IB Hilton, GE Crawford, TE Reddy, and CA Gersbach. "CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome." Nature Biotechnology 35, no. 6 (2017): 561-568.
S Chakraborty, H Ji, AM Kabadi, CA Gersbach, N Christoforou, and KW Leong. "A CRISPR/Cas9-based system for reprogramming cell lineage specification." Stem Cell Reports 3, no. 6 (2014): 940-947.
PI Thakore, and CA Gersbach. "Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors." Methods in molecular biology (Clifton, N.J.) 1338 (2016): 71-88.

Pages